MY188367A - Crystalline forms glyt1 - Google Patents

Crystalline forms glyt1

Info

Publication number
MY188367A
MY188367A MYPI20092584A MYPI20092584A MY188367A MY 188367 A MY188367 A MY 188367A MY PI20092584 A MYPI20092584 A MY PI20092584A MY PI20092584 A MYPI20092584 A MY PI20092584A MY 188367 A MY188367 A MY 188367A
Authority
MY
Malaysia
Prior art keywords
glyt1
preparation
crystalline forms
present
methanone
Prior art date
Application number
MYPI20092584A
Other languages
English (en)
Inventor
Pinard Emmanuel
Gerard Bubendorf Andre
Schwitter Urs
Rohrer Franziska
Olaf Grassmann
Annette Deynet-Vucenovic
Ralph Diodone
Kai Lindenstruth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY188367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY188367A publication Critical patent/MY188367A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MYPI20092584A 2006-12-28 2007-12-18 Crystalline forms glyt1 MY188367A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
MY188367A true MY188367A (en) 2021-12-06

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20092584A MY188367A (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (enExample)
EP (1) EP2114405B1 (enExample)
JP (1) JP4799666B2 (enExample)
KR (1) KR101130146B1 (enExample)
CN (1) CN101573114A (enExample)
AR (1) AR064545A1 (enExample)
AU (1) AU2007341356B2 (enExample)
BR (1) BRPI0720829B8 (enExample)
CA (1) CA2673667A1 (enExample)
CL (1) CL2007003830A1 (enExample)
CO (1) CO6190613A2 (enExample)
CR (1) CR10846A (enExample)
CY (1) CY1116350T1 (enExample)
DK (1) DK2114405T3 (enExample)
EC (1) ECSP099471A (enExample)
ES (1) ES2535040T3 (enExample)
HR (1) HRP20150573T1 (enExample)
HU (1) HUE025032T2 (enExample)
MA (1) MA31029B1 (enExample)
MX (1) MX2009006859A (enExample)
MY (1) MY188367A (enExample)
NO (1) NO342150B1 (enExample)
NZ (1) NZ577502A (enExample)
PE (1) PE20081556A1 (enExample)
PL (1) PL2114405T3 (enExample)
PT (1) PT2114405E (enExample)
RS (1) RS53910B1 (enExample)
RU (1) RU2463295C2 (enExample)
SI (1) SI2114405T1 (enExample)
TW (1) TWI388552B (enExample)
UA (1) UA100232C2 (enExample)
WO (1) WO2008080821A1 (enExample)
ZA (1) ZA200904423B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ,インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
EP2855462A1 (en) * 2012-05-25 2015-04-08 Basf Se Crystalline form b of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
WO2022014397A1 (ja) * 2020-07-13 2022-01-20 日本碍子株式会社 精製方法
AU2022273051A1 (en) * 2021-05-14 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
CN101573114A (zh) 2006-12-28 2009-11-04 弗·哈夫曼-拉罗切有限公司 结晶形式glyt1

Also Published As

Publication number Publication date
US20080214561A1 (en) 2008-09-04
PT2114405E (pt) 2015-06-02
BRPI0720829B8 (pt) 2021-05-25
AU2007341356A1 (en) 2008-07-10
US8039473B2 (en) 2011-10-18
CY1116350T1 (el) 2017-03-15
BRPI0720829A2 (pt) 2014-02-25
TW200833677A (en) 2008-08-16
AU2007341356B2 (en) 2013-08-29
UA100232C2 (uk) 2012-12-10
CN101573114A (zh) 2009-11-04
BRPI0720829B1 (pt) 2020-04-07
NZ577502A (en) 2012-02-24
KR101130146B1 (ko) 2012-03-28
CA2673667A1 (en) 2008-07-10
PL2114405T3 (pl) 2015-08-31
MX2009006859A (es) 2009-07-03
CO6190613A2 (es) 2010-08-19
SI2114405T1 (sl) 2015-06-30
CR10846A (es) 2009-08-12
RS53910B1 (sr) 2015-08-31
AR064545A1 (es) 2009-04-08
CL2007003830A1 (es) 2008-07-11
ZA200904423B (en) 2010-05-26
HUE025032T2 (en) 2016-02-29
HRP20150573T1 (xx) 2015-07-03
PE20081556A1 (es) 2008-11-28
US20130197225A1 (en) 2013-08-01
ECSP099471A (es) 2009-07-31
JP4799666B2 (ja) 2011-10-26
KR20090094166A (ko) 2009-09-03
EP2114405B1 (en) 2015-03-11
DK2114405T3 (en) 2015-04-07
RU2463295C2 (ru) 2012-10-10
US20110295007A1 (en) 2011-12-01
MA31029B1 (fr) 2009-12-01
ES2535040T3 (es) 2015-05-04
NO20092358L (no) 2009-06-22
TWI388552B (zh) 2013-03-11
US20120309969A1 (en) 2012-12-06
US20100311971A1 (en) 2010-12-09
JP2010514725A (ja) 2010-05-06
EP2114405A1 (en) 2009-11-11
WO2008080821A1 (en) 2008-07-10
NO342150B1 (no) 2018-04-03
RU2009124113A (ru) 2011-02-10

Similar Documents

Publication Publication Date Title
MY188367A (en) Crystalline forms glyt1
MXPA06002727A (es) Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis.
TNSN06042A1 (en) Piperazine with or-substituted phenyl group and their use as glyt 1 inhibitors
IN2012DN00766A (enExample)
CU20110106A7 (es) Nuevos compuestos 578
EA200901373A1 (ru) Аминогетероциклические соединения
MY141229A (en) Piperidine-benzenesulfonamide derivatives
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
TW200633957A (en) Compounds
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
GB0428232D0 (en) Compounds
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
TW200633956A (en) Compounds
MX2009010729A (es) Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EA200870492A1 (ru) N-оксиды производных пиридилметилпиперазина и - пиперидина
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
TH92210B (th) รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone)
TH107358A (th) รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone)
MX2010008239A (es) 2-aminoquinolinas.
IN2009CN03566A (enExample)